GTx slapped with "surprise" complete response letter for toremifene
This article was originally published in Scrip
Executive Summary
The US FDA has unexpectedly hit GTx with a complete response letter for its oral selective oestrogen receptor modulator, toremifene 80mg, for a new indication for the prevention of bone fractures in men with prostate cancer who are receiving androgen deprivation therapy (ADT) to treat their cancer.
You may also be interested in...
P&G to co-promote Somaxon's Silenor in the US
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GSK's shingles vaccine begins Phase III studies
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
Optimer's fidaxomicin filing accepted in EU
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.